Abcam, ab251501, Anti-Biglycan antibody [EPR20235] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Biglycan antibody. Carrier free. Suitable for IHC-P and reacts with Human samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR20235,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251501 is the carrier-free version of
ab209234
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Biglycan also known as BGN is a small leucine-rich proteoglycan with a molecular weight of roughly 38 kDa. Researchers frequently observe Biglycan in tissues such as bone cartilage and vasculature. The protein interacts with several other molecules in the extracellular matrix (ECM) including collagen and elastin to maintain the structural integrity of tissues. Through these interactions Biglycan plays an important role in supporting cell attachment and matrix organization.
Biological function summary
The protein Biglycan influences cellular processes such as growth and differentiation. It is part of a complex network within the ECM that modulates cell signaling. Biglycan interacts with growth factors like transforming growth factor-beta (TGF-beta) and binds to Toll-like receptors (TLRs) affecting immune responses. These capabilities reveal Biglycan’s involvement in tissue development and repair.
Pathways
Extracellular matrix modulation shows a significant role for Biglycan. It is involved in the TGF-beta signaling pathway and the inflammatory pathway mediated by TLRs. Through these pathways Biglycan interacts with proteins such as decorin and fibromodulin contributing to the regulation of collagen fibrillogenesis and inflammatory responses. Its role in these pathways highlights Biglycan’s influence in cellular communication and matrix regulation.
Biglycan has associations with osteoarthritis and muscular dystrophy. In osteoarthritis researchers observe altered expression levels of Biglycan which affects cartilage integrity. In muscular dystrophy the protein’s connection to dystrophin an important structural protein is noted. These associations illustrate Biglycan's impact on disease progression and its potential as a therapeutic target.